表紙
市場調査レポート

糖尿病治療薬の世界市場およびパイプライン製品の分析 (2015年)

Global Diabetes Drug Market & Pipeline Insight 2015

発行 KuicK Research 商品コード 327762
出版日 ページ情報 英文 1100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
糖尿病治療薬の世界市場およびパイプライン製品の分析 (2015年) Global Diabetes Drug Market & Pipeline Insight 2015
出版日: 2015年04月03日 ページ情報: 英文 1100 Pages
概要

全世界で糖尿病患者が急増するのに伴い、アンメットニーズも急速に拡大し、巨大な市場機会が生み出されつつあります。巨額の研究資金が投じられた結果、新たな治療薬が多数開発され、短期間に次々と上市されていくでしょう。市場規模も今後数年間で数倍に拡大する見通しです。

当レポートでは、世界各国における糖尿病治療薬市場の動向、およびパイプライ製品の開発状況について分析し、糖尿病治療薬の特性や作用機序、全体的な市場構造・動向、パイプライン製品の現在の開発状況、製品単位 (計817製品) および治験段階別の詳細な開発状況、上市済み製品 (計99製品) の販売状況、適応症別の詳細動向、今後の市場の方向性といった情報をお届けいたします。

第1章 糖尿病の概略

第2章 糖尿病治療薬の機序

第3章 世界の糖尿病治療薬市場の概要

  • 現在の市場シナリオ
  • 糖尿病治療薬の臨床パイプラインの概況

第4章 世界の糖尿病治療薬市場のダイナミクス

  • 良好な市場指標
  • 開発・商業化に際しての課題

第5章 世界の糖尿病治療薬市場の将来展望

第6章 糖尿病性神経障害の治療薬の臨床パイプライン:企業別・相 (フェーズ) 別

  • 認証までの治験・研究活動状況
  • 上市済み医薬品の臨床分析

第7章 糖尿病性腎症の治療薬の臨床パイプライン:企業別・相別

第8章 糖尿病の治療薬の臨床パイプライン:企業別・相別

第9章 1型糖尿病性腎症の治療薬の臨床パイプライン:企業別・相別

第10章 2型糖尿病性腎症の治療薬の臨床パイプライン:企業別・相別

第11章 糖尿病性足部潰瘍の治療薬の臨床パイプライン:企業別・相別

第12章 糖尿病性黄斑浮腫の治療薬の臨床パイプライン:企業別・相別

第13章 糖尿病性胃アトニーの治療薬の臨床パイプライン:企業別・相別

第14章 糖尿病性網膜症の治療薬の臨床パイプライン:企業別・相別

第15章 前糖尿病状態の治療薬の臨床パイプライン:企業別・相別

第16章 糖尿病治療薬の臨床パイプライン:企業別・相別

第17章 企業プロファイル

  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lily
  • GalaxoSmithKline
  • Johnson & Johnson
  • MannKind Corporation
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

図表一覧

目次

Diabetes market is a rapidly growing segment with numerous products at different stages of clinical pipeline and others at different phases of industry life cycle. Disease incidences are escalating rapidly across the globe due to which high unmet demand has been created and pharmaceutical companies are trying to provide efficient medical care to patients. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criterias set by medical regulatory authorities. Number of diabetes drugs for treatment is increasing every year due to which their market shares are expected to increase further in coming years.

Diabetes drug delivery is a mature field which provides lots of opportunities to the pharmaceutical companies to market their products. Innovation seems to be the key to success because it is quite mature and without novel functionality it doesn't seem meaningful to enter in such a competitive market segment. Increased investments in research and development segment are expected to introduce competitive products at cost effective prices in short time. It shows that the diabetes drug market segment would be filled with innovative products that would be able to offer better diabetes management to patients. In this way, it could be expected that this market would be able to grow several folds, generate significant revenues and prevent morbidity caused by diabetes.

Several molecules belonging to different classes like carbohydrate digestion inhibitors, sulphonyl urea, insulin sensitizers and others are being screened for their effects on diabetes. They have to prove their candidature by providing better safety and efficacy profiles than existing diabetes drugs. Rigorous clinical trials would be required to prove their pharmacological worthiness for effectively treating diabetes patients. These molecules are known to have cytotoxicity due to which they may have side effects but by modulating its design such problems could be overcome by investigators. On the other hand, these molecules are easy to produce and offer higher cost effectiveness due to which pharmaceutical companies have become interested in their research and development. In coming years, more molecules of these types are expected to enter in global market which would be affordable by large number of patients belonging to different socio-economic groups.

Besides screening of novel molecules, emphasis on discovering different pathways have been given by investigators for developing diabetes drugs with higher safety and efficacy profiles. Insulin pathway is one of the most studied pathways that have been widely targeted by investigators to maintain blood glucose levels. Diabetes drugs that target cellular receptors have been made which works at molecular levels because they have higher control over insulin regulation. Some drug molecules increase the glucose uptake in cells to decrease blood glucose levels. On the other hand, there are diabetes drugs that act on the gastrointestinal tract and prevent the carbohydrate digestion in the body. Investigators have developed many methods to control diabetes and several innovative mechanisms are being studied to come forth with better products. As a result, more products will be launched due to which their market penetration is expected to increase in coming years.

Diabetes Drug Pipeline by Segment in Report:

  • Diabetic Neuropathies
  • Diabetic Nephropathies
  • Diabetes Mellitus
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
  • Diabetic Foot Ulcer
  • Diabetic Macular Oedema
  • Diabetic Gastroparesis
  • Diabetic Retinopathy
  • Diabetes Insipidus
  • Prediabetic State

"Global Diabetes Drug Market & Pipeline Insight 2015" Report Highlight:

  • Global Diabetes Drug Market Overview
  • Global Diabetic Drug Clinical Pipeline by Company & Phase
  • Global Diabetic Drug Clinical Pipeline: 817 Drugs
  • Majority in Preclinical Phase: 205 Drugs
  • Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
  • Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
  • Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
  • Marketed Diabetic Drugs: 99 Drugs

Table of Contents

1. Introduction to Diabetes

2. Diabetes Drug Mechanism

3. Global Diabetes Drug Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Global Diabetes Drug Pipeline Overview

4. Global Diabetes Drug Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Development & Commercialization Challenges

5. Global Diabetes Drug Market Future Prospects

6. Diabetic Neuropathies Drug Clinical Pipeline by Company & Phase

  • 6.1 Research to till Registered
  • 6.2 Marketed Drug Clinical Insight

7. Diabetic Nephropathies Drug Clinical Pipeline by Company & Phase

  • 7.1 Research to till Registered
  • 7.2 Marketed Drug Clinical Insight

8. Diabetes Mellitus Drug Clinical Pipeline by Company & Phase

  • 8.1 Phase Research to till Registered
  • 8.2 Marketed Drug Clinical Insight

9. Type 1 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase

  • 9.1 Research to till Registered
  • 9.2 Marketed Drug Clinical Insight

10. Type 2 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase

  • 10.1 Research to till Registered
  • 10.2 Marketed Drug Clinical Insight

11. Diabetic Foot Ulcer Drug Clinical Pipeline by Company & Phase

  • 11.1 Research to till Phase-III
  • 11.2 Marketed Drug Clinical Insight

12. Diabetic Macular Oedema Drug Clinical Pipeline by Company & Phase

  • 12.1 Research to till Registered
  • 12.2 Marketed Drug Clinical Insight

13. Diabetic Gastroparesis Drug Clinical Pipeline by Company & Phase

  • 13.1 Preclinical to till Phase-III
  • 13.2 Marketed Drug Clinical Insight

14. Diabetic Retinopathy Drug Clinical Pipeline by Company & Phase

  • 14.1 Research to till Phase-III

15. Prediabetic State Drug Clinical Pipeline by Company & Phase

  • 15.1 Phase-II

16. Diabetes Drug Clinical Pipeline by Company & Phase

  • 16.1 Research to till Registered
  • 16.2 Marketed Drug Clinical Insight

17. Competitive Landscape

  • 17.1 AstraZeneca
  • 17.2 Boehringer Ingelheim
  • 17.3 Eli Lily
  • 17.4 GalaxoSmithKline
  • 17.5 Johnson & Johnson
  • 17.6 MannKind Corporation
  • 17.7 Merck
  • 17.8 Novartis
  • 17.9 Pfizer
  • 17.10 Sanofi

List of Figures and Tables

  • Figure 1-1: Types of Diabetes
  • Figure 1-2: Diseases Associated with Diabetes
  • Figure 1-3: Diabetes Causing Factors
  • Figure 2-1: Function of Insulin
  • Figure 2-2: Mechanism of Metformin
  • Figure 2-3: Mechanism of Pramlintide
  • Figure 2-4: Mechanism of Sulphonylureas
  • Figure 2-5:Mechanism of Alpha-Glycosidase Inhibitors
  • Figure 2-6:Mechanism of Thiazolidinediones
  • Figure 3-1: Global Diabetes Incidences (Million), 2014 & 2035
  • Figure 3-2:Global Distribution of Diabetes Patients (Million), 2014
  • Figure 3-3: Diabetec Neuropathies Pipeline by Phase(%), 2015
  • Figure 3-4: Diabetec Neuropathies Pipeline by Phase(Number), 2015
  • Figure 3-5: Diabetic Nephropathies Pipeline by Phase(%), 2015
  • Figure 3-6: Diabetic Nephropathies Pipeline by Phase(Number), 2015
  • Figure 3-7: Diabetes Mellitus Pipeline by Phase(%), 2015
  • Figure 3-8: Diabetes Mellitus Pipeline by Phase(Number), 2015
  • Figure 3-9: Type 1 Diabetes Mellitus Pipeline by Phase(%), 2015
  • Figure 3-10: Type 1 Diabetes Mellitus Pipeline by Phase(Number), 2015
  • Figure 3-11: Type 2 Diabetes Mellitus Pipeline by Phase(%), 2015
  • Figure 3-12: Type 2 Diabetes Mellitus Pipeline by Phase(Number), 2015
  • Figure 3-13: Diabetic Foot Ulcer Pipeline by Phase(%), 2015
  • Figure 3-14: Diabetic Foot Ulcer Pipeline by Phase(Number), 2015
  • Figure 3-15: Diabetic Macular Oedema Pipeline by Phase(%), 2015
  • Figure 3-16: Diabetic Macular Oedema Pipeline by Phase(Number), 2015
  • Figure 3-17: Diabetic Gastroparesis Pipeline by Phase(%), 2015
  • Figure 3-18: Diabetic Gastroparesis Pipeline by Phase(Number), 2015
  • Figure 3-19: Diabetic Retinopathy Pipeline by Phase(%), 2015
  • Figure 3-20: Diabetic Retinopathy Pipeline by Phase(Number), 2015
  • Figure 3-21: Diabetes Insipidus Pipeline by Phase(%), 2015
  • Figure 3-22: Diabetes Insipidus Pipeline by Phase(Number), 2015
  • Figure 3-23: Multiple Diabetic Pipeline by Phase(%), 2015
  • Figure 3-24: Multiple Diabetic Pipeline by Phase(Number), 2015
  • Figure 4-1: Global Diabetes Drug Market Favorable Parameters
Back to Top